Search research articles
Contact Us
Filters
Showing results (91-100 of 111) with videos related to
Page
of 12
Sort By:
SAGE Open Medicine
|
November 1, 2024
Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome
Dragana Protic, Elizabeth Breeze, Guadalupe Mendoza, et al.
Scientific Reports
|
January 26, 2019
Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach
Robert Kueffner, Neta Zach, Maya Bronfeld, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
October 14, 2021
ALSUntangled #63: ketogenic diets
Richard Bedlack, Paul E Barkhaus, Benjamin Barnes, et al.
The Journal of Clinical Investigation
|
August 31, 2023
Effects of AFQ056 on language learning in fragile X syndrome
Elizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, et al.
The Journal of Clinical Investigation
|
July 17, 2018
Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models
Alex McCampbell, Tracy Cole, Amy J Wegener, et al.
Plos One
|
December 7, 2007
Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery
Katrina Gwinn, Roderick A Corriveau, Hiroshi Mitsumoto, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
July 5, 2024
Allogeneic B cell immunomodulatory therapy in amyotrophic lateral sclerosis
Ruxandra F Sîrbulescu, Katharine Nicholson, Kento Kawai, et al.
Plos One
|
May 21, 2014
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial
Vincent Meininger, Pierre-François Pradat, Andrea Corse, et al.
Muscle & Nerve
|
December 19, 2022
Safety and activity of anti-CD14 antibody IC14 (atibuclimab) in ALS: Experience with expanded access protocol
Dario Gelevski, Grace Addy, Margot Rohrer, et al.
The New England Journal of Medicine
|
July 9, 2020
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
Timothy Miller, Merit Cudkowicz, Pamela J Shaw, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 111) with videos related to
Sort By:
Page
of 12
SAGE Open Medicine
|
November 1, 2024
Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome
Dragana Protic, Elizabeth Breeze, Guadalupe Mendoza, et al.
Scientific Reports
|
January 26, 2019
Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach
Robert Kueffner, Neta Zach, Maya Bronfeld, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
October 14, 2021
ALSUntangled #63: ketogenic diets
Richard Bedlack, Paul E Barkhaus, Benjamin Barnes, et al.
The Journal of Clinical Investigation
|
August 31, 2023
Effects of AFQ056 on language learning in fragile X syndrome
Elizabeth Berry-Kravis, Leonard Abbeduto, Randi Hagerman, et al.
The Journal of Clinical Investigation
|
July 17, 2018
Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models
Alex McCampbell, Tracy Cole, Amy J Wegener, et al.
Plos One
|
December 7, 2007
Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery
Katrina Gwinn, Roderick A Corriveau, Hiroshi Mitsumoto, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
July 5, 2024
Allogeneic B cell immunomodulatory therapy in amyotrophic lateral sclerosis
Ruxandra F Sîrbulescu, Katharine Nicholson, Kento Kawai, et al.
Plos One
|
May 21, 2014
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trial
Vincent Meininger, Pierre-François Pradat, Andrea Corse, et al.
Muscle & Nerve
|
December 19, 2022
Safety and activity of anti-CD14 antibody IC14 (atibuclimab) in ALS: Experience with expanded access protocol
Dario Gelevski, Grace Addy, Margot Rohrer, et al.
The New England Journal of Medicine
|
July 9, 2020
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
Timothy Miller, Merit Cudkowicz, Pamela J Shaw, et al.
Page
of 12